You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《新股消息》亞盛醫藥(06855.HK)料核心藥物最快於2021年商業化(更正)
阿思達克 10-28 10:25

亞盛醫藥(06855.HK)公布在主板上市計劃,聯合創始人兼首席執行官楊大俊在記者會上表示,公司有8項處臨床階段的小分子候選藥物,其中核心藥物「HQP1351」的關鍵二期臨床試驗持續,公司計劃明年為該藥申請上市註冊許可,如臨床數據滿意及獲監管批准,最快可於2021年商業化。

公司是次上市引入中生製藥(01177.HK)作為基石投資者,認購相當於2,000萬美元股份。楊大俊稱未來與中生製藥有很多機會探討合作空間,但是次對方是次投資者身份入股。

對於公司此前打算在美國上市,及有否考慮在內地科創板上市,他指2017年初公司作B輪融資後曾考慮在美國上市,但其後香港聯交所容許未錄盈利生物科技企業在港上市,公司認為政策利好,香港市場亦符合公司特點,因此選擇在港上市。楊氏提到,公司目前希望將研發做好及專注香港市場,但未來也不排除尋找符合公司發展需求的資本市場機會。

另外,被問及是次集資規劃僅約4億元,與公司完成C輪融資後的約60億元估值有差距,首席財務官張甦指公司C輪融資集資額較大,截至今年6月仍有約7億元人民幣資金,是次集資規模是考慮了公司自身需求及藥物管線進展等因素。

(更正:2019-10-16 11:30:12 《新股消息》亞盛醫藥

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account